Key Highlights:
- Rusan Healthcare has launched the APOSAN 3ml Pen (apomorphine hydrochloride) in India, a multi-dose delivery device designed to manage ‘ON-OFF’ motor fluctuations in Parkinson’s disease patients
- The pre-filled cartridge pen features a dial-a-dose mechanism and enhanced dose visibility, enabling accurate, portable, and user-friendly subcutaneous administration, supporting rapid symptom relief and safer self-management at home
- The launch expands Rusan’s apomorphine portfolio, including injections and infusion pumps, while being supported by the APOSAN HOPE patient program, reinforcing access to advanced Parkinson’s care amid a rising and younger disease burden globally
Implications:
Rusan’s new APOSAN 3 ml multi‑dose pen broadens at‑home rescue options for Indian Parkinson’s patients by adding a dial‑a‑dose, cartridge‑based apomorphine device on top of its existing injections and infusion pumps.
By pairing the pen with the APOSAN HOPE support program, covering training, onboarding, and nursing assistance, Rusan is lowering the practical barriers to using advanced apomorphine therapy, which is increasingly relevant as Parkinson’s prevalence and earlier‑onset cases rise globally.
Source: Express Pharma | Image: Rusan Healthcare
